[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Oncology Inc (CTOR)

Citius Oncology Inc (CTOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,264
  • Shares Outstanding, K 92,981
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,760 K
  • EBIT $ -44 M
  • EBITDA $ -44 M
  • 60-Month Beta 3.47
  • Price/Sales 10.22
  • Price/Cash Flow N/A
  • Price/Book 1.70
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings $-0.27 on 05/15/26
  • Next Earnings Date 08/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6100 +11.54%
on 06/26/26
0.8000 -14.95%
on 06/08/26
-0.1021 (-13.05%)
since 06/02/26
3-Month
0.6100 +11.54%
on 06/26/26
0.9995 -31.93%
on 04/23/26
-0.0226 (-3.21%)
since 04/02/26
52-Week
0.4912 +38.52%
on 03/30/26
5.8899 -88.45%
on 07/03/25
-4.5396 (-86.97%)
since 07/02/25

Most Recent Stories

More News
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated...

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ®

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad...

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain conditions

CTOR : 0.6804 (-3.39%)
Citius Oncology Ships First International Order of LYMPHIRâ„¢ to Europe

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Oncology Provides Commercial Update on LYMPHIRâ„¢ Launch Highlighting Early Adoption and Expanding Clinical Development

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIRâ„¢ in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.5746 (-5.63%)
CTOR : 0.6804 (-3.39%)
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response...

CTOR : 0.6804 (-3.39%)

Business Summary

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

See More

Key Turning Points

3rd Resistance Point 0.7718
2nd Resistance Point 0.7459
1st Resistance Point 0.7131
Last Price 0.6804
1st Support Level 0.6544
2nd Support Level 0.6285
3rd Support Level 0.5957

See More

52-Week High 5.8899
Fibonacci 61.8% 3.8276
Fibonacci 50% 3.1906
Fibonacci 38.2% 2.5535
Last Price 0.6804
52-Week Low 0.4912

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.